Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection
Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection
复制标题
细胞因子诱导的杀伤细胞免疫辅助治疗对结直肠癌根治术后患者的疗效
DOI：
10.1080/2162402x.2020.1752563
复制
发表时间：
2020-01-01
期刊：
影响因子：
7.2
通讯作者：
Xia, Jian-Chuan
中科院分区：
文献类型：
--
作者：
Pan, Qiu-Zhongi;Zhao, Jing-Jing;Xia, Jian-Chuan
手术后辅助化疗是III期和部分II期或IV期结直肠癌（CRC）患者的标准治疗方式。然而，5年总生存率（OS）仍然不令人满意。因此，开发联合治疗对于改善CRC患者的预后至关重要。本研究的目的是确定序贯联合应用苦参碱诱导的杀伤细胞（CIK）输注和化疗对结直肠癌患者的疗效。回顾性分析了122例接受术后辅助化疗的结直肠癌患者。其中，62例患者仅接受辅助化疗（对照组），而其他60例患者，具有相似的人口统计学和临床特征，接受辅助化疗和序贯CIK细胞免疫治疗（CIK组）。生存分析显示，与对照组相比，CIK组的无病生存期（DFS）和OS率显著提高（对数秩检验，P = 0.0024; P = 0.008）。单因素和多因素分析显示，序贯CIK细胞治疗是影响患者DFS和OS的独立预后因素。亚组分析显示，序贯CIK细胞治疗可显著改善高危T4期和化疗时间不足患者的DFS和OS。总之，这些数据表明，序贯辅助CIK细胞治疗联合化疗是预防疾病复发和延长CRC患者生存期的有效治疗策略，特别是对于高危T4分期和化疗持续时间不足的患者。
ABSTRACT Adjuvant chemotherapy after surgery is the standard treatment modality for stage III and part of stage II or stage IV colorectal cancer (CRC) patients. However, the 5-year overall survival (OS) rate remains unsatisfactory. Thus, developing combination therapies is essential to improve the prognosis of patients with CRC. The present study aimed to determine the effect of a sequential combination of cytokine-induced killer cell (CIK) infusion and chemotherapy for patients with CRC. 122 patients with CRC treated with postoperative adjuvant chemotherapy were retrospectively included in this study. Among them, 62 patients received adjuvant chemotherapy only (control group), while the other 60 patients, with similar demographic and clinical characteristics, received adjuvant chemotherapy and sequential CIK cell immunotherapy (CIK group). Survival analysis showed significantly improved disease free survival (DFS) and OS rates in the CIK group compared with the control group (log-rank test, P = .0024; P = .008, respectively). Univariate and multivariate analyses indicated that sequential CIK cell treatment was an independent prognostic factor for patients’ DFS and OS. Subgroup analyses showed that sequential CIK cell treatment significantly improved the DFS and OS of patients with high-risk T4 stage and insufficient chemotherapy duration. In conclusion, these data indicate that sequential adjuvant CIK cell treatment combined with chemotherapy is an effective therapeutic strategy to prevent disease recurrence and prolong survival of patients with CRC, particularly for patients with high-risk T4 stage and insufficient chemotherapy duration.